nafamostat has been researched along with Hypertension, Pulmonary in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kreil, E | 1 |
| Montalescot, G | 1 |
| Greene, E | 1 |
| Fitzgibbon, C | 1 |
| Robinson, D | 1 |
| Chenoweth, D | 1 |
| Zapol, WM | 1 |
1 other study available for nafamostat and Hypertension, Pulmonary
| Article | Year |
|---|---|
Nafamstat mesilate attenuates pulmonary hypertension in heparin-protamine reactions.
Topics: Animals; Benzamidines; Blood Pressure; Complement C3a; Complement Inactivator Proteins; Drug Interac | 1989 |